Elicio Therapeutics, Inc. (ticker: ELTX) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of ELTX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. ELTX reported $0 in revenue and -$11.82M for the period ending 2023-03-31, with operating cash flow of -$11.64M. Cash and equivalents stood at $14.95M (down 18.5% year-over-year). Total assets of $22.69M are exceeded by total liabilities of $24.13M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
ELTX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Elicio Therapeutics, Inc. (ELTX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.